Accurate Prediction of Breast Cancer Survival through Coherent Voting Networks with Gene Expression Profiling - Pellegrini, Marco (medRxiv, 2020)
We describe a novel machine learning methodology which we call Coherent Voting Network (CVN) and we demonstrate its usefulness by building a 5-years prognostic predictor for post-surgery breast cancer patients based on CVNs. Coherent Voting Network (CVN) is a supervised learning paradigm designed explicitly to uncover non-linear, combinatorial patterns in complex data, within a statistical robust framework. Breast Cancer patients after surgery may receive several types of post-surgery adjuvant therapeutic regimen (endocrine, radio- or chemo-therapy, and combinations thereof) aiming at reducing relapse and the formation of metastases, and thus favouring log term survival. We wish to predict the outcome of adjuvant therapy using just small molecular fingerprints (mRNA) of the patient’s transcriptome. Our aim is to have simultaneously high scores for PPV (positive predictive value) and NPV (negative predictive value) as these are important indices for the final clinical applications of the predictor. A Training-validate-test protocol is applied onto CVN built on patient data from the Metabric Consortium (about 2000 patients). For the testing pool of 82 lymph node positive patients we obtain PPV 0.77 and NPV 0.78 (Odds Ratio 11.50); for the pool of 61 lymph node negative patients we obtain PPV 0.68 and NPV 0.88 (Odds Ratio 16.07). Improved results are obtained on some specific sub-types of BC. For the testing pool of 16 TNBC patients we obtain PPV 1.0 and NPV 0.83 (Odds Ratio 45.00). For the testing pool of 18 HER2+ patients we obtain PPV 0.91 and NPV 1.0 (Odds Ratio 40.00). For the testing pool of 41 Luminal B patients we obtain PPV 0.75 and NPV 0.95 (Odds Ratio 60.00). Effectiveness of the selected fingerprints is confirmed also on several independent data sets (for a total of 601 patients) from the NCBI Gene Expression Omnibus (GEO).Competing Interest StatementDr. Pellegrini reports In addition, Dr. Pellegrini has a patent EP 20202942.7 pending to National Research Council of Italy, a patent IT 102019000019571 pending to National Research Council of Italy, a patent IT 102019000019556 pending to National Research Council of Italy, and a patent US 17/077,294 pending to National Research Council of Italy.Funding StatementThe research exposed in this article has been conducted as curiosity-driven free research by the author.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research uses only data in public repositories.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available at https://github.com/MarcoPellegriniCNR/Coherent-Voting-Network-for-BC-prognosis https://github.com/MarcoPellegriniCNR/Coherent-Voting-Network-for-BC-prognosis